Is Spyre Therapeutics Stock a Good Investment?
Spyre Therapeutics Investment Advice | SYRE |
- Examine Spyre Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Spyre Therapeutics' leadership team and their track record. Good management can help Spyre Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Spyre Therapeutics' business and its evolving consumer preferences.
- Compare Spyre Therapeutics' performance and market position to its competitors. Analyze how Spyre Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Spyre Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Spyre Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Spyre Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Spyre Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Spyre Therapeutics Stock
Researching Spyre Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 88.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 37.9. Spyre Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 8th of September 2023.
To determine if Spyre Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spyre Therapeutics' research are outlined below:
| Spyre Therapeutics had very high historical volatility over the last 90 days | |
| Spyre Therapeutics was previously known as AGLE Old and was traded on NASDAQ Exchange under the symbol AGLE. | |
| The company reported the previous year's revenue of 886 K. Net Loss for the year was (338.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Spyre Therapeutics generates negative cash flow from operations | |
| Spyre Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Spyre Therapeutics Announces Pricing of 200 Million Public Offering of Common Stock |
Spyre Therapeutics Quarterly Cash And Short Term Investments |
|
Spyre Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spyre Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spyre Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Spyre Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Spyre Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-11-08 | 2017-09-30 | -0.55 | -0.48 | 0.07 | 12 | ||
2016-11-08 | 2016-09-30 | -0.55 | -0.47 | 0.08 | 14 | ||
2017-03-08 | 2016-12-31 | -0.46 | -0.56 | -0.1 | 21 | ||
2024-11-07 | 2024-09-30 | -0.82 | -1.36 | -0.54 | 65 | ||
2021-08-05 | 2021-06-30 | -0.1644 | -2.5 | -2.3356 | 1420 | ||
2024-02-29 | 2023-12-31 | -0.78 | -4.05 | -3.27 | 419 | ||
2022-11-03 | 2022-09-30 | -0.25 | -4.33 | -4.08 | 1632 | ||
2023-05-11 | 2023-03-31 | -0.18 | -4.55 | -4.37 | 2427 |
Spyre Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.61 B.Market Cap |
|
Spyre Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (0.78) | (0.82) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | (1.84) | (1.93) |
Determining Spyre Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Spyre Therapeutics is a good buy. For example, gross profit margin measures Spyre Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spyre Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Spyre Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spyre Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spyre Therapeutics' management manipulating its earnings.
Evaluate Spyre Therapeutics' management efficiency
Spyre Therapeutics has return on total asset (ROA) of (0.3881) % which means that it has lost $0.3881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9162) %, meaning that it created substantial loss on money invested by shareholders. Spyre Therapeutics' management efficiency ratios could be used to measure how well Spyre Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -1.04. In addition to that, Return On Capital Employed is expected to decline to -0.82. At present, Spyre Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 358.6 M, whereas Non Currrent Assets Other are forecasted to decline to 8,550.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 26.68 | 25.35 | |
| Tangible Book Value Per Share | 26.68 | 25.35 | |
| Enterprise Value Over EBITDA | (0.18) | (0.19) | |
| Price Book Value Ratio | 0.81 | 0.77 | |
| Enterprise Value Multiple | (0.18) | (0.19) | |
| Price Fair Value | 0.81 | 0.77 | |
| Enterprise Value | 44.1 M | 77.9 M |
The strategic initiatives led by Spyre Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 2.91 |
Basic technical analysis of Spyre Stock
As of the 22nd of November, Spyre Therapeutics has the Coefficient Of Variation of 3235.74, semi deviation of 4.17, and Risk Adjusted Performance of 0.0313. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Spyre Therapeutics, as well as the relationship between them. Please validate Spyre Therapeutics standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Spyre Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 27.0 per share. Given that Spyre Therapeutics has jensen alpha of (0.11), we advise you to double-check Spyre Therapeutics's current market performance to make sure the company can sustain itself at a future point.Spyre Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spyre Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spyre Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spyre Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Spyre Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Spyre Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0313 | |||
| Market Risk Adjusted Performance | 0.0521 | |||
| Mean Deviation | 3.02 | |||
| Semi Deviation | 4.17 | |||
| Downside Deviation | 4.34 | |||
| Coefficient Of Variation | 3235.74 | |||
| Standard Deviation | 3.81 | |||
| Variance | 14.49 | |||
| Information Ratio | 0.0058 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | 0.0051 | |||
| Treynor Ratio | 0.0421 | |||
| Maximum Drawdown | 15.8 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 5.3 | |||
| Downside Variance | 18.79 | |||
| Semi Variance | 17.42 | |||
| Expected Short fall | (2.97) | |||
| Skewness | (0.54) | |||
| Kurtosis | (0.34) |
| Risk Adjusted Performance | 0.0313 | |||
| Market Risk Adjusted Performance | 0.0521 | |||
| Mean Deviation | 3.02 | |||
| Semi Deviation | 4.17 | |||
| Downside Deviation | 4.34 | |||
| Coefficient Of Variation | 3235.74 | |||
| Standard Deviation | 3.81 | |||
| Variance | 14.49 | |||
| Information Ratio | 0.0058 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.32) | |||
| Sortino Ratio | 0.0051 | |||
| Treynor Ratio | 0.0421 | |||
| Maximum Drawdown | 15.8 | |||
| Value At Risk | (6.81) | |||
| Potential Upside | 5.3 | |||
| Downside Variance | 18.79 | |||
| Semi Variance | 17.42 | |||
| Expected Short fall | (2.97) | |||
| Skewness | (0.54) | |||
| Kurtosis | (0.34) |
Consider Spyre Therapeutics' intraday indicators
Spyre Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Spyre Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 65754.86 | |||
| Daily Balance Of Power | (0.21) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 27.93 | |||
| Day Typical Price | 27.62 | |||
| Price Action Indicator | (1.18) | |||
| Period Momentum Indicator | (0.50) | |||
| Relative Strength Index | 71.35 |
Spyre Therapeutics Corporate Filings
| 19th of November 2024 Other Reports | ViewVerify | |
8K | 18th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Spyre Stock media impact
Far too much social signal, news, headlines, and media speculation about Spyre Therapeutics that are available to investors today. That information is available publicly through Spyre media outlets and privately through word of mouth or via Spyre internal channels. However, regardless of the origin, that massive amount of Spyre data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Spyre Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Spyre Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Spyre Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Spyre Therapeutics alpha.
Spyre Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Spyre Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Spyre Therapeutics Corporate Management
| James JD | Consultant | Profile | |
| Janet MBA | Senior Operations | Profile | |
| Eric McIntyre | Vice Relations | Profile | |
| Deanna MD | Senior Development | Profile | |
| CFE CPA | Vice Controller | Profile | |
| Justin LaFountaine | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Spyre Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.